PCI Pharma Services Completes Acquisition of Ajinomoto Althea

Bain Capital and Kohlberg Lead Strategic Investment in PCI Pharma Services

July 14, 2025

Healthcare Services

PCI Pharma Services, a Philadelphia-based contract development and manufacturing organization (CDMO), received a strategic growth investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala and a continuing minority stake from Partners Group. The capital will be used to accelerate PCI's organic and inorganic growth, expand sterile fill-finish and specialized manufacturing capacity, and broaden its geographic footprint to support biopharma customers and U.S. pharmaceutical supply-chain resilience.

Jabil Acquires Pharmaceutics International (Pii)

February 6, 2025

Pharmaceuticals

Jabil has acquired Pharmaceutics International (Pii), a Hunt Valley, Maryland-based contract development and manufacturing organization (CDMO) that provides aseptic filling, lyophilization and oral solid dose manufacturing. The all-cash transaction represents an exit for a consortium led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc., and brings Pii’s ~300+ employees and four-site campus into Jabil’s Pharmaceutical Solutions offering to expand its drug development and manufacturing capabilities.

PCI Pharma Services Acquires LSNE to Expand Sterile Fill-Finish and Lyophilization Capabilities

October 12, 2021

Healthcare Services

PCI Pharma Services (PCI) signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a Bedford, New Hampshire-based contract development and manufacturing organization (CDMO), from Permira. The deal was closed in December 2021, adding LSNE’s lyophilization and sterile fill-finish capabilities and expanding PCI’s global CDMO network.

Kohlberg & Mubadala Acquire Majority Stake in PCI Pharma Services

December 1, 2020

Healthcare Services

Private equity firm Kohlberg & Company acquired a majority stake in PCI Pharma Services, with Mubadala Investment Company joining as a significant investor and Partners Group retaining a minority stake. The deal (signed August 24, 2020 and closed December 1, 2020) positions PCI to expand capabilities—such as sterile fill/finish and high-potency manufacturing—and further geographic reach while continuing to serve pharmaceutical and biopharmaceutical customers from its Philadelphia headquarters.

Alcami Acquires TriPharm Services to Expand Sterile Fill‑Finish Capacity

January 17, 2020

Pharmaceuticals

Alcami Corporation has acquired TriPharm Services, a new sterile fill‑finish manufacturing center near Research Triangle Park, North Carolina. Funds affiliated with Alcami majority owner Madison Dearborn Partners made an additional equity investment to support Alcami's growth plan, while Ampersand Capital Partners rolled a portion of its TriPharm ownership into Alcami.

Novacap Acquires PCI Synthesis

June 28, 2018

Pharmaceuticals

Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.